Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GLS-5700

Vaccine (DNA plasmid) · Immune activation, directed at Zika virus prME proteins · developed by GeneOne Life Science

Phase 1 Most advanced trial (none active)
1 Registered trials

What is GLS-5700?

GLS-5700 is a plasmid DNA vaccine encoding Zika virus pre-membrane and envelope proteins. It is designed to induce immune responses against Zika virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (DNA plasmid)
Targets
Zika virus prME proteins (antigen)
Mechanism
Immune activation, directed at Zika virus prME proteins
Pathways
immune_activation
Therapy area
Infectious disease
Developer
GeneOne Life Science, Inc.
In trials of
INO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02809443 Phase 1 Healthy Completed INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.